Skip to main content
. 2020 Jan 1;10(3):1122–1135. doi: 10.7150/thno.37851

Figure 3.

Figure 3

Selective inhibition of PDGFRβ impairs tumor vascularization in LLC and B16/PDGF-BB tumors. LLC (A-F) and B16/PDGF-BB (G-L) tumors were grown in ASKA PDGFRβ mutant mice. After treatment with 1-NaPP1 or imatinib for 10 consecutive days, sections from tumors were immunostained for podocalyxin (LLC tumors; A) and CD31 (B16/PDGF-BB; G); podocalyxin/CD31, green; DAPI, blue; >20 field 200x magnification images were scored for each mouse (n=5 or more animals). Scale bar, 50 µM. Vascular parameters were analyzed using the Angiotool software. Vessel density expressed as a percentage of the tumor area (B, H), average vessel length (C, I), branching (junction density; D, J), number of junctions (E, K) and average lacunarity (F, L) of LLC (B-F) and B16/PDGF-BB tumors (H-L), are shown. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. Each data point corresponds to one individual mouse (n=5 or more animals).